Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gabapentin

J Bruni1

  • 1Division of Neurology, Wellesley Hospital, University of Toronto, Canada.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Gabapentin is an effective adjunctive therapy for partial and generalized tonic-clonic seizures in adults. Further research is needed to define its role in pediatric epilepsy and as monotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group.

Seizure·2000
Same author

Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group.

Seizure·2000
Same author

A STAT cardiac marker system for detecting acute heart attacks.

American clinical laboratory·1999
Same author

Gabapentin as adjunctive therapy for partial seizures.

Epilepsia·1999
Same author

Women's issues in the treatment of epilepsy.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·1998
Same author

Efficacy of topiramate.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·1998
Same journal

Practice Patterns and Care Gaps in Lennox Gastaut Syndrome: A call for Action.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Isolated Achiasma Discovered at Age 86: A Rare Cause of see-saw nystagmus and bitemporal hemianopia.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Post-Stroke Parakinesia Brachialis Oscitans: Clinical Insights from a Case Series.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

A Neuronal Perspective.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Diagnostic efficacy, costs, and safety of portable ultra-low field MRI in brain imaging: a systematic review.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Chronology of Non-Motor Symptoms in 100 Patients with Advanced PD of 10 Years' Duration: Pre- versus Post-Motor Period.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
See all related articles

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Gabapentin is a newly introduced antiepileptic drug.
  • Its precise mechanism of action is not yet fully understood.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of gabapentin in epilepsy treatment.
  • To identify areas for further clinical investigation.

Main Methods:

  • Clinical studies were conducted to assess gabapentin's effectiveness.
  • Pharmacokinetic profiles and tolerability were evaluated.

Main Results:

  • Gabapentin demonstrates efficacy in various seizure models, predicting effectiveness in partial and tonic-clonic seizures.
  • Clinical trials confirm gabapentin's efficacy as adjunctive therapy in adults with specific seizure types.

Related Experiment Videos

  • The drug exhibits a favorable pharmacokinetic profile and is generally well-tolerated.

    • Conclusions:

    • Gabapentin is a promising adjunctive treatment for adult epilepsy.
    • Additional data on pediatric use and monotherapy are necessary to fully establish its role in epilepsy management.